Epion is developing a minimally invasive treatment for an ectatic corneal disease.
Epion Therapeutics has raised $32.0M in total funding. The most recent round was Series A. The last funding was announced in September 2022.
Epion Therapeutics's investors include Global Health Investment Fund (GHIF).
Epion Therapeutics is headquartered in Burlington, United States.
Epion is developing a minimally invasive treatment for an ectatic corneal disease.
Epion Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Epion Therapeutics — Funding & Investors." VCBacked, September 30, 2022, https://www.vcbacked.co/company/epion-therapeutics. Accessed September 29, 2026.
VCBacked. (2022). Epion Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/epion-therapeutics
{{cite web |title=Epion Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/epion-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated